iomeprol has been researched along with Obesity in 1 studies
iomeprol: structure given in first source
iomeprol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rengo, M | 1 |
| Bellini, D | 1 |
| Businaro, R | 1 |
| Caruso, D | 1 |
| Azzara, G | 1 |
| De Santis, D | 1 |
| Picchia, S | 1 |
| Biondi, T | 1 |
| Eid, M | 1 |
| Boschiero, D | 1 |
| Laghi, A | 1 |
1 trial available for iomeprol and Obesity
| Article | Year |
|---|---|
MDCT of the liver in obese patients: evaluation of a different method to optimize iodine dose.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Electric Impedance; Female; Humans; Iopamidol; Liver | 2017 |